Results 211 to 220 of about 16,485 (256)

Natural killer cells. Lymphokine-activated killers

2008
Tumors can escape from adaptive immune reactions mediated by cytotoxic T-lymphocytes via down-regulation or complete loss of major histocompatibility class I molecules. Some, and perhaps most, of tumors also seem to lack tumor-specific antigens that may be recognized by adaptive immunity.
Evgenia O. Khalturina, Mikhail V. Kiselevsky, Irina O. Chikileva, Olga V. Lebedinskaya, Irina Zh. Shubina   +4 more
openaire   +2 more sources

Phenotypic characterization of murine lymphokine-activated killer cells

Cellular Immunology, 1986
Short-term culture of murine lymphocytes in interleukin 2 (IL-2), in the absence of any priming antigen, has been shown to result in the differentiation of an activated killer cell population capable of potent cytotoxic activity against tumor cells. The progenitor and lineage of these lymphokine activated killer cells (LAK) remains controversial.
Samuel R. Abraham, George P. Hemstreet, Laurie B. Owen-Schaub   +2 more
openaire   +3 more sources

Lymphokine-activated killer cells, natural killer cells and cytokines

Current Opinion in Immunology, 1991
In the past year, natural killer cells have been the subject of much active investigation. The analysis of the effect of cytokines on the generation, proliferation and function of natural killer cells, and the definition of the lymphokines that they produce, have been particularly important areas of research in view of their possible application in ...
openaire   +3 more sources

Lysis of human monocytes by lymphokine-activated killer cells

Cellular Immunology, 1988
Human peripheral blood leukocytes (PBL), stimulated in vitro with recombinant human interleukin 2 (IL-2) for 2-7 days, were seen to lyse autologous and allogeneic monocytes in a 4-hr 51Cr-release assay. The lymphokine-activated killer (LAK) cells against monocytic cells were selective in that polymorphonuclear leukocytes (PMN) and nonadherent PBLs were
Julie Y. Djeu, D. Kay Blanchard
openaire   +3 more sources

Enhancement of Lymphokine-Activated Killer Cell Activity by Fibronectin

Journal of Immunotherapy, 1997
In this study, we demonstrated that immobilized fibronectin (FN) enhanced lymphokine-activated killer cell (LAK) activity, and that the enhanced LAK activity was completely abrogated by an anti-VLA-5 monoclonal antibody and RGD peptide. Fresh spleen cells expressed VLA-4, VLA-6, and vitronectin receptor, whereas VLA-5 was expressed only on the spleen ...
Ko Okumura, Kazuhiro Matsushita, Lan Yuan, Yasuhiro Kuramitsu, Yong-qing Li, Masanobu Kobayashi, Masuo Hosokawa, Hideo Yagita   +7 more
openaire   +3 more sources

Lymphokine-activated killer cell activity after cryopreservation

Journal of Immunological Methods, 1989
The effect of cryopreservation on the cytotoxic activity of lymphokine-activated killer (LAK) cells was studied. LAK cells were generated by incubating peripheral blood lymphocytes for 3-5 days with recombinant interleukin-2 (rIL-2) and then cryopreserved using a programmed freezer. Cytotoxicity was determined in a 51Cr release assay.
Ingo G.H. Schmidt-Wolf, Aihara M, Robert S. Negrin, Karl G. Blume, Nelson J. Chao   +4 more
openaire   +3 more sources

Glutamine requirements in the generation of lymphokine-activated killer cells

Clinical Nutrition, 1994
The role of glutamine (GLN) in the generation of lymphokine-activated killer (LAK) cell activity was investigated. LAK cells were derived from healthy donors and peripheral blood mononuclear cells (PBMC) were obtained using either unseparated PMBC or DR(-) CD3(-) CD16(+) CD56(+) enriched cells. PBMC were cultured for 6 or 10 days in medium supplemented
Reto Babst, Michael Heberer, Giulio C. Spagnoli, H. Hörig, K. von Bremen, Antonio Juretić, Felix Harder   +6 more
openaire   +3 more sources

Technical aspects of lymphokine‐activated killer cell production

Journal of Clinical Apheresis, 1988
AbstractAdoptive immunotherapy is a novel approach to treating patients with cancer, utilizing as therapy a patient's own peripheral blood lymphocytes that have been activated by incubation with interleukin‐2 (IL‐2). These cells develop the ability to mediate tumor regression in vivo and are referred to as lymphokine‐activated killer (LAK) cells.
Charles S. Carter, Steven A. Rosenberg, Linda M. Muul, Herb Cullis, Harvey G. Klein, Kathryn Nason-Burchenal, Susan F. Leitman   +6 more
openaire   +3 more sources

The regulatory effect of adherent cells on lymphokine activated killer cells

Cellular Immunology, 1987
We analyzed the effect of adherent cells on the induction of lymphokine-activated killer (LAK) cell activity by depleting adherent cells from peripheral blood lymphocytes (PBL) or by adding adherent cells to PBL before culture with interleukin-2. We found that adherent cells clearly down-regulate LAK cell induction.
Dave S.B. Hoon, Sidney H. Golub, Yukihiro Ibayashi   +2 more
openaire   +3 more sources

Lymphokine-activated killer cells are rejected in vivo by activated natural killer cells

The Journal of Immunology, 1991
Abstract A 4-h in vivo cytotoxicity assay was used to study the fate of implanted IL-2-generated, lymphokine-activated killer (LAK) cells in mice undergoing an activated NK cell response. 125Iododeoxyuridine-labeled LAK cells were rejected from selected organs of C57BL/6 mice infected with lymphocytic choriomeningitis virus or treated ...
J O, Brubaker, K T, Chong, R M, Welsh
openaire   +2 more sources